A New way of treating Hypertensio
Not Applicable
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2019/02/017473
- Lead Sponsor
- Kasturba Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 74
Inclusion Criteria
Subjects, newly diagnosed with Essential Hypertension of Stage 1 with SBP ranging between 140-159 mmHg and/or DBP ranging between 90-99 mmHg as per JNC classification
Exclusion Criteria
1) Subjects with secondary hypertension
2)Subjects with known CV risk factors, diabetes mellitus.
3)Subjects with any significant abnormalities on a 12-lead ECG
4)Subjects with known neuromuscular disorders
5)History of alcoholism (alcohol abuse) and cannot refrain from alcohol consumption during the study period.
6)History of smoking ( >1 pack per day or >20 cigarettes) and cannot refrain from smoking during the study period
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To evaluate and compare the effects on the arterial stiffness (AS) in newly diagnosed hypertensives being treated with either azilsartan or benidipineTimepoint: Two Followups for 3 and 6 months after being enrolled. <br/ ><br>Total duration for study - 18 months
- Secondary Outcome Measures
Name Time Method 2.To determine the factors contributing to the arterial stiffness. <br/ ><br>3.To determine the prognostic value of non-invasive arterial stiffness assessment by pulse wave analysis automatic device Mobil-O-Graph�® <br/ ><br>Timepoint: To be concluded by July 2020